Trial Profile
A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational
- Sponsors Gilead Sciences
- 27 Sep 2022 Results assessing the effect of A Daily Single Tablet Regimen of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in Virologically suppressed Adults Living With HIV & End Stage Renal Disease on Chronic Hemodialysis presented at the 2022 American College of Clinical Pharmacology Annual Meeting
- 25 Oct 2020 Results presented at the IDWeek 2020
- 22 Oct 2019 Status changed from active, no longer recruiting to completed.